Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 312 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Nasal Spray Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of AL-53817 Nasal Spray Solution

NCT01454505
View directory record Official record
Conditions
Nasal Allergies, Allergies
Interventions
AL-53817 nasal spray solution, Vehicle nasal spray
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 2, 2026, 2:05 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Triadic Interactions of Families With Autism and Oxytocin

NCT01912378
View directory record Official record
Conditions
Autism Disorder
Interventions
Oxytocin, Placebo nasal spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

NCT00845858
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus, Delayed Gastric Emptying
Interventions
metoclopramide, Placebo
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
65
States / cities
Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS

NCT00539006
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FPNS, FFNS, placebo FPNS, placebo FFNS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
24
States / cities
Scottsdale, Arizona • Fresno, California • Huntington Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 2, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

NCT06364228
View directory record Official record
Conditions
Stress
Interventions
Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

NCT01277341
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day, Placebo Nasal Spray
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin, Emotions and Mirror Neurons

NCT02228031
View directory record Official record
Conditions
Social Cognition, Expressed Emotion
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Effects of Oxytocin Nasal Spray on Social Affiliation

NCT00663039
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

NCT03275922
View directory record Official record
Conditions
Migraine
Interventions
Placebo ZNS, ZNS
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin, Alcohol Craving, and Intimate Partner Aggression

NCT03046836
View directory record Official record
Conditions
Alcohol Use
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

NCT01944046
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Double blind phase Placebo Nasal Spray, double Blind Oxytocin Nasal Spray, Open Label intranasal oxytocin
Drug
Lead sponsor
Linmarie Sikich
Other
Eligibility
3 Years to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • White Plains, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional

Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD

NCT03211013
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Oxytocin, Placebos
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 2, 2026, 2:05 AM EDT
Terminated Phase 4 Interventional Results available

Fentanyl for Breakthrough Pain in the Emergency Department

NCT01812759
View directory record Official record
Conditions
Pain
Interventions
Fentanyl Nasal Spray, Hydromorphone PCA, Placebo Nasal Spray
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
80 mcg Ciclesonide, 160 mcg Ciclesonide, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

NCT00712920
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
43
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Allergic Rhinitis Changes the Sinus Microbiome

NCT01852513
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
QNASL, Placebo nasal spray
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

NCT06546423
View directory record Official record
Conditions
Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions
B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Months to 59 Months
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine

NCT01807234
View directory record Official record
Conditions
Migraines
Interventions
Ketorolac, Sumatriptan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

NCT00959764
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Oral Calcitonin Tablets, Intranasal Calcitonin, Placebo tablets and placebo intranasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Huntsville, Alabama • Oakland, California • Palm Desert, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 2, 2026, 2:05 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

NCT05045508
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) Nasal Spray
Drug
Lead sponsor
Brandon Baartman
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Results available

Oxytocin, Stress, Craving, Opioid Use Disorder

NCT04051619
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
intranasal oxytocin, 40 IU, twice a day for 7 days
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 2, 2026, 2:05 AM EDT